On demand recording available

Key challenges in AAV manufacturing, such as residual manufacturing costs, DNA contamination, and supply chain complexities limit patient access to gene therapies. Understanding and addressing these issues is crucial to the sustained advancement of therapeutics and their availability for various indications.



Michael DiBiasio-White (Head of Process Development and Manufacturing Innovations, Affinia Therapeutics),
Ying Cai (Executive Director, Manufacturing Science and Technology, Ultragenyx Therapeutics),
Roland Pach (Global Analytical Expert, CMC, CGT, & Alternative Formats, Roche) 
share insights on how to achieve a successful and efficient AAV manufacturing process, supporting the breakthrough of advanced gene therapies in Cell&Gene's webinar:

• Discover the current trends and advancements in AAV manufacturing and understand the latest technologies and methodologies shaping the field

• Find out how to identify the primary obstacles in AAV manufacturing, with a focus on both upstream and downstream considerations, including cost, analytics, supply chain, and efficiency

• Receive practical tips and expert advice for successful implementation and best practices to optimize both upstream and downstream AAV production, in-house or outsourced